[FDA] In a rolling submission (also known as rolling review), a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA. Thus the overall timeline for review is shortened.<\/p>\n","protected":false},"excerpt":{"rendered":"
[FDA] In a rolling submission (also known as rolling review), a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section is completed before the entire application can be reviewed. BLA or NDA review usually does not begin […]<\/p>\n","protected":false},"author":232,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","footnotes":""},"categories":[180,199],"tags":[],"type_content":[179],"job":[],"employees_type":[],"class_list":["post-20249","post","type-post","status-publish","format-standard","hentry","category-glossary","category-r","type_content-glossaire","entry"],"acf":[],"yoast_head":"\n